Introduction One of the potential sources for the occurrence of various systemic pathologies, such as cardiovascular diseases, cerebrovascular diseases, and respiratory diseases is periodontitis. Testing of glycosylated hemoglobin (HbA) is a highly standardized procedure and is becoming increasingly popular these days due to its cost-effectiveness and ease of use. Literature quotes numerous studies associating the periodontal diseases with various hemoglobin markers in diabetic and nondiabetic patients. Hence, we planned the present study to assess the levels of HbA in patients with periodontitis among nondiabetic patients. Materials and methods For the present study, a total of 50 nondiabetic subjects who reported to the department with the chief complaint of periodontitis were included. Another set of 50 nondiabetic individuals were included in the present study of comparable age in whom no periodontitis was detected clinically. Clinical examination and radiographic evaluation was performed for the selection of the cases for the study group. The patients were sent to the laboratory after the clinical examination, for the testing of HbA. Testing of the hemoglobin A1c (HbA1c) levels of all the subjects and controls was performed and values were noted and evaluated. Results Nonsignificant results were obtained while comparing the mean HbA1c concentrations among the study group and the control group. Nonsignificant results were obtained while comparing the mean HbA1c levels among males and females. While comparing the mean HbA1c levels between the study group and the control group divided on the basis of body mass index, nonsignificant results were obtained. Conclusion In nondiabetic subjects, no significant correlation could be observed between periodontitis and HbA1c levels. Clinical significance The HbA1c cannot be used as a reliable maker for differentiation of patients with periodontal pathologies from patients free of periodontal pathologies. How to cite this article Wahi S, Tripathi A, Wahi S, Mishra VD, Singh AP, Sinha N. Assessment of Levels of Glycosylated Hemoglobin in Patients with Periodontal Pathologies: A Comparative Study. J Contemp Dent Pract 2017;18(6):506-509.

No abstract

No abstract

Background: Two Transcatheter Aortic Valve Implant (TAVI) devices are currently in use under clinical trial in Australia -Edwards SAPIEN valve (SAPIEN) andMedtronic CoreValve (CoreValve). Anatomical suitability for SAPIEN include: aortic annulus dimension of 18-25 mm, iliac-femoral diameter >7-8 mm (transfemoral approach using 22-24 Fr RetroFlex system) or >6-6.5 mm (transfemoral approach using newer 18-19 NovaFlex system). Anatomical suitability for CoreValve include: aortic annulus dimension of 20-27 mm, ascending aorta diameter ≤40-43 mm, iliac-femoral diameter >6 mm (for transfemoral approach) or left subclavian diameter >6 mm (for transubclavian approach). We aim to assess the complementary anatomical suitability in a TAVI program with access to both valves.Methods and results: Fifty-five patients were treated with TAVI in a single centre with simultaneous access to both SAPIEN and CoreValve since February 2009. Twenty were implanted using CoreValve (all transfemoral) and 35 using SAPIEN (12 transapical, 15 transfemoral with RetroFlex system, 8 with NovaFlex system). Aortic annulus was measured using transoesophageal echocardiogram. Iliac-femoral, subclavian, ascending aortic and root anatomy were measured using invasive angiography. Fifty patients (91%) were suitable for SAPIEN valve, with 21 being suitable for transfemoral approach using RetroFlex system and 38 with NovaFlex system. Forty-four patients (80%) were suitable for CoreValve, with 36 being suitable for transfemoral approach. Overall 45 cases were suitable for a transfemoral approach using one or both valves.Conclusion: 9-20% of the patients treated in this centre with access to both transcatheter valves would be unsuitable for treatment if there was access to only one valve. 82% can be treated with a transfemoral approach.

No abstract